Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
617 articles
Johns Hopkins research finds combining cannabis edibles with alcohol impairs driving far beyond either substance alone, evading standard sobriety tests.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
A 48,904-patient meta-analysis finds prasugrel reduces heart attacks and stent clots better than its rivals after PCI.
A new JAMA Cardiology analysis warns that rising temperatures and a growing elderly population are converging to produce an unprecedented cardiac emergency.
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A phase 1 trial tests RBD7022, a novel subcutaneous RNA-based therapy, for safety and dosing in adults with high LDL cholesterol.
A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.
Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.
